Novartis has released the positive results from its Phase III trial of Leqvio.
The pharmaceutical company was investigating the use of Leqvio (inclisiran) as a monotherapy for the prevention of atherosclerotic cardiovascular disease (ASCVD) in patients who aren't receiving lipid-lowering therapy.
The V-MONO study found that Leqvio as a monotherapy had a significant effect on the levels of low-density lipoprotein cholesterol (LDL) compared to placebo and ezetimibe — the current standard of care.
Leqvio is a small siRNA therapy, which is designed to lower LDL cholesterol levels in patients at low to moderate risk of developing ASCVD.
The drug, according to Novartis, should be administered twice annually to function optimally.
Novartis is currently running studies in other areas to determine the small molecule's therapeutic potential outside of LDL cholesterol management.
“We are proud that we continue to advance the scientific understanding of using siRNA therapy to tackle one of the world’s biggest healthcare challenges, as too many people still struggle to reach their cholesterol goals,” said Shreeram Aradhye, M.D., President, Development and Chief Medical Officer, Novartis.
“This trial adds to the growing body of evidence for Leqvio across the full spectrum of ASCVD as we strive to help more patients in need.”
[Image credit: Drugs.com]
